CUSIP: G0750W203
Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,372,861
-
Share change
-
+303,104
-
Total reported value
-
$21,784,497
-
Put/Call ratio
-
62%
-
Price per share
-
$6.46
-
Number of holders
-
37
-
Value change
-
+$1,988,656
-
Number of buys
-
17
-
Number of sells
-
17
Quarterly Holders Quick Answers
What is CUSIP G0750W203?
CUSIP G0750W203 identifies AXGT - AXOVANT GENE THERAPIES LTD - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2019
-
Previous quarter:
Q2 2019
Recent filing periods for CUSIP G0750W203:
Institutional Holders of AXOVANT GENE THERAPIES LTD - COM (AXGT) as of Q3 2019
As of 30 Sep 2019,
AXOVANT GENE THERAPIES LTD - COM (AXGT) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,372,861 shares.
The largest 10 holders included
SPHERA FUNDS MANAGEMENT LTD., CITADEL ADVISORS LLC, Hudson Bay Capital Management LP, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Caption Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., PRIMECAP MANAGEMENT CO/CA/, Marshall Wace North America L.P., and SUSQUEHANNA INTERNATIONAL GROUP, LLP.
This page lists
37
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.